Ads
related to: hydrochlorothiazide/lisinopril warnings for sale 1
Search results
Results From The WOW.Com Content Network
Lisinopril/hydrochlorothiazide, sold under the brand name Zestoretic among others, is a fixed-dose combination medication used for the treatment of high blood pressure (hypertension). [2] It contains lisinopril , an ACE inhibitor , and hydrochlorothiazide , a diuretic .
Enalapril/hydrochlorothiazide (trade name Enalapril comp), wherein enalapril is the ACE inhibitor and hydrochlorothiazide is the thiazide. Quinapril/hydrochlorothiazide (trade name Accuretic) [2] Lisinopril/hydrochlorothiazide is marketed as Prinzide, [3] Zestoretic, [4] and many others.
Lisinopril leaves the body completely unchanged in the urine. [1] [16] The half-life of lisinopril is 12 hours, and is increased in people with kidney problems. [1] [16] While the plasma half-life of lisinopril has been estimated between 12 and 13 hours, the elimination half-life is much longer, at around 30 hours. [18]
Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. [4] Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in those with a high calcium level in the urine . [ 4 ]
ATC code C09 Agents acting on the renin–angiotensin system is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
If you love Scrabble, you'll love the wonderful word game fun of Just Words. Play Just Words free online!
Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors.It is used for essential (primary) hypertension. [2] While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit.
Almost 23% had three hours of daily screen time, 17.8% had two hours, 6.1% had one hour, and only 3% had less than one hour, according to a report from the CDC's National Center for Health Statistics.